ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

Share this content:
ASTRO: No Survival Benefit for Adding EBT to Brachytherapy
ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- Among men with intermediate-risk prostate cancer, the addition of external beam therapy (EBT) to transperineal interstitial permanent brachytherapy (B) does not improve five-year progression-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 25 to 28 in Boston.

Bradley R. Prestidge, M.D., from the DePaul Medical Center in Norfolk, Va., and colleagues randomized men with prostate cancer to receive 45 Gy partial pelvis EBT + B or B alone. Five hundred eighty-eight men were randomized (287 EBT + B eligible and 292 B eligible); patients were followed for a median of 6.7 years.

The researchers found that five-year progression-free survival was 85 percent for the EBT + B arm and 86 percent for the B arm at the fifth interim analysis of 443 patients with five years of follow-up (hazard ratio, 1.02; futility P = 0.0006). The Data Monitoring Committee recommended early release for the initial reporting of the primary end point. Similar acute overall ≥ grade 3 toxicity was seen (8 percent for EBT + B and B). Overall ≥ grade 3 late toxicity was 12 and 7 percent for EBT + B and B, respectively.

"These findings suggest that many men with intermediate risk prostate cancer can be well managed with seed implant alone and do not require the addition of external beam radiation," Prestidge said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Florida Teen First Human Case of Another Mosquito-Borne Virus

Florida Teen First Human Case of Another Mosquito-Borne ...

First documented case of Keystone infection in a human

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

Illnesses reported in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio, and Tennessee

AAFP Still Recommends CRC Screening From Age 50 to 75

AAFP Still Recommends CRC Screening From Age 50 ...

Despite ACS change to start screening from age 45 years, AAFP agrees with USPSTF recommendation

is free, fast, and customized just for you!




Already a member?

Sign In Now »